|Third party request
|Prophylactic neutralizing Ab
|Study Start Date:
|Study Made Public:
Immunogenicity of heterologous boost immunizations with MVA-CMDR, a modified vaccinia Ankara HIV-1 vaccine expressing Env gp 150/gag/pol, in HIV-uninfected volunteers previously immunized with DCVax-001 plus poly-ICLC
CAVD 579 (SSC-0803 or TP 22) is a phase I study to evaluate the safety and immunogenicity of heterologous boost immunizations with MVA-CMDR in HIV-uninfected healthy participants previously immunized with the monoclonal antibody, DCVax-001, plus Hiltonol® in CAVD 264 (DC Vax).
Sign in to see full information about this study and to download study data.